CRISPR Therapeutics
CRSP
443 hedge funds and large institutions have $5.19B invested in CRISPR Therapeutics in 2021 Q1 according to their latest regulatory filings, with 107 funds opening new positions, 175 increasing their positions, 96 reducing their positions, and 71 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 175 | Existing positions reduced: 96
51% more first-time investments, than exits
New positions opened: 107 | Existing positions closed: 71
8% more funds holding
Funds holding: 412 → 443 (+31)
9% less call options, than puts
Call options by funds: $360M | Put options by funds: $396M
9.32% less ownership
Funds ownership: 66.31% → 56.99% (-9.3%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
28% less capital invested
Capital invested by funds: $7.23B → $5.19B (-$2.04B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$129M |
| 2 |
Two Sigma Advisers
New York
|
+$101M |
| 3 |
FP
Financial Perspectives
Minneapolis,
Minnesota
|
+$55.9M |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$46.7M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$42.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$386M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$321M |
| 3 |
VVM
Versant Venture Management
San Francisco,
California
|
-$224M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$71.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$51.3M |
CRSP Hedge Fund Activity: Q1 2021 in Review
443 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2021, worth a combined $5.19B — down 28% from $7.23B a quarter earlier.
Buyers outnumbered sellers: 107 funds opened new CRSP positions and 71 closed out — a net gain of 36 holders — while 175 added to existing stakes and 96 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $129M. The largest seller was Capital International Investors, cutting an estimated $386M.
- 443 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2021, up from 412 in Q4 2020.
- Funds reported $5.19B of CRISPR Therapeutics stock for Q1 2021, down 28% quarter-over-quarter.
- 107 funds opened new CRISPR Therapeutics positions in Q1 2021 and 71 closed out, a net change of +36 holders.
- The largest CRISPR Therapeutics buyer in Q1 2021 was Two Sigma Investments, an estimated $129M added.
- The largest CRISPR Therapeutics seller in Q1 2021 was Capital International Investors, an estimated $386M sold.
Based on aggregated 13F filings for Q1 2021.